Shots:

• Lineage to receive an upfront payment in cash and- if the option is exercised- Lineage will be eligible for additional payments- including event-specific payments- royalties on net sales and sublicense fees and royalties
• Amasa gets an exclusive option to royalty-bearing license to use Lineage’s HyStem technology to develop and commercialize therapies for solid tumors under pre-negotiated terms
• Amasa will buy some amounts of Lineage’s existing supply of clinical-grade HyStem biomaterial and has the right to buy additional quantities in up to 12-mos. option to acquire the exclusive license

  | Ref: Business Wire | Image: Lineage Cell